@foxmeadon.bsky.social
Reposted
We’re excited to announce the first patient has been dosed in our Phase 1 clinical trial of OKN4395, a first-in-class EP2/EP4/DP1 triple inhibitor for solid tumors.
Learn more in STAT’s latest interview with Andrew Pierce, Owkin’s SVP Discovery & Development: www.statnews.com/2025/01/30/o...
Learn more in STAT’s latest interview with Andrew Pierce, Owkin’s SVP Discovery & Development: www.statnews.com/2025/01/30/o...
How AI helps drug developers skirt pharma’s ‘dirty little secret’
Andrew Pierce, senior executive at French biotech Owkin, on how artificial intelligence can make the drug development process more efficient.
www.statnews.com
January 30, 2025 at 4:38 PM
We’re excited to announce the first patient has been dosed in our Phase 1 clinical trial of OKN4395, a first-in-class EP2/EP4/DP1 triple inhibitor for solid tumors.
Learn more in STAT’s latest interview with Andrew Pierce, Owkin’s SVP Discovery & Development: www.statnews.com/2025/01/30/o...
Learn more in STAT’s latest interview with Andrew Pierce, Owkin’s SVP Discovery & Development: www.statnews.com/2025/01/30/o...